FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3035951108> ?p ?o ?g. }

• W3035951108 endingPage "1003" @default.
• W3035951108 startingPage "997" @default.
• W3035951108 abstract "ABSTRACTIntroduction The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has rapidly grown into a public health emergency that has placed the national health systems as well as scientific research communities under enormous pressures. Drug repurposing or repositioning is a well-known strategy that seeks to deploy existing licensed drugs for newer indications and provides the quickest possible transition from bench to clinics for unmet therapeutic needs. Given the current, urgent, and dire need for effective therapies against novel coronavirus-19, this approach is particularly appealing.Areas covered Here, we review the significant anti-inflammatory, immunomodulatory, and antiviral properties of minocycline as potential mechanisms for efficacy against the novel coronavirus and highlight the promises and pitfalls of this approach.Expert opinion As compared to other agents being investigated for COVID-19, minocycline offers distinct advantages in terms of potential efficacy in patients with life-threatening acute respiratory distress syndrome (ARDS) and myocardial injury, well-known safety and interaction profile, relatively low costs, and widespread availability. We call upon public and private funders to facilitate urgent and rigorous research efforts before evidence-based recommendations for its widespread use can be made.KEYWORDS: MinocyclineCOVID-19SARS-CoV-2drug repurposingcytokine stormARDSmyocardial injury Article highlightsDrug repurposing offers several advantages over traditional novel drug development and provides the quickest possible transition from bench to bedside.Minocycline, a well characterized tetracycline, possesses significant anti-inflammatory, immunomodulatory, antiapoptotic, and antioxidant actions in addition to its antibiotic properties.Based on these non-antibiotic activities, this article reviews the potential mechanisms for its efficacy against the novel coronavirus and highlights the promises and pitfalls of this approachFor COVID-19 patients, minocycline offers advantages in terms of potential efficacy in acute respiratory distress syndrome (ARDS) and myocardial injury, well-known safety profile, low costs, and widespread availability.Given the urgent need for COVID-19 specific therapies, public and private health sectors must facilitate high quality robust research to characterize the efficacy and safety of minocycline in COVID-19 patients.Declaration of interestThe authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.Reviewer disclosuresPeer reviewers on this manuscript have no relevant financial or other relationships to disclose.Additional informationFundingThis paper was not funded." @default.
• W3035951108 created "2020-06-25" @default.
• W3035951108 creator A5055733515 @default.
• W3035951108 creator A5056279223 @default.
• W3035951108 creator A5060211163 @default.
• W3035951108 date "2020-07-01" @default.
• W3035951108 modified "2023-10-17" @default.
• W3035951108 title "Repurposing minocycline for COVID-19 management: mechanisms, opportunities, and challenges" @default.
• W3035951108 cites W1582413398 @default.
• W3035951108 cites W1966034545 @default.
• W3035951108 cites W1969696108 @default.
• W3035951108 cites W1975447710 @default.
• W3035951108 cites W1980081550 @default.
• W3035951108 cites W1988958914 @default.
• W3035951108 cites W1993589138 @default.
• W3035951108 cites W2003877973 @default.
• W3035951108 cites W2027215365 @default.
• W3035951108 cites W2047871833 @default.
• W3035951108 cites W2077591301 @default.
• W3035951108 cites W2094964008 @default.
• W3035951108 cites W2105847002 @default.
• W3035951108 cites W2111123843 @default.
• W3035951108 cites W2120490119 @default.
• W3035951108 cites W2122311826 @default.
• W3035951108 cites W2133961780 @default.
• W3035951108 cites W2138086361 @default.
• W3035951108 cites W2156719192 @default.
• W3035951108 cites W2157482683 @default.
• W3035951108 cites W2166673123 @default.
• W3035951108 cites W2267315119 @default.
• W3035951108 cites W2422251210 @default.
• W3035951108 cites W2749515418 @default.
• W3035951108 cites W2765985736 @default.
• W3035951108 cites W2802309637 @default.
• W3035951108 cites W2850687326 @default.
• W3035951108 cites W2896002881 @default.
• W3035951108 cites W2904662596 @default.
• W3035951108 cites W2966514066 @default.
• W3035951108 cites W2966890571 @default.
• W3035951108 cites W3001118548 @default.
• W3035951108 cites W3004280078 @default.
• W3035951108 cites W3007940623 @default.
• W3035951108 cites W3008028633 @default.
• W3035951108 cites W3009314935 @default.
• W3035951108 cites W3009885589 @default.
• W3035951108 cites W3009976289 @default.
• W3035951108 cites W3011324254 @default.
• W3035951108 cites W3011439019 @default.
• W3035951108 cites W3012421327 @default.
• W3035951108 cites W3012747666 @default.
• W3035951108 cites W3013231340 @default.
• W3035951108 cites W3013302817 @default.
• W3035951108 cites W3013685277 @default.
• W3035951108 cites W3014003872 @default.
• W3035951108 cites W3018307241 @default.
• W3035951108 cites W3019247800 @default.
• W3035951108 cites W3019682307 @default.
• W3035951108 cites W3021826725 @default.
• W3035951108 cites W3022970339 @default.
• W3035951108 cites W3023991776 @default.
• W3035951108 cites W4206245015 @default.
• W3035951108 cites W4206805526 @default.
• W3035951108 cites W4230173358 @default.
• W3035951108 doi "https://doi.org/10.1080/14787210.2020.1782190" @default.
• W3035951108 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32552044" @default.
• W3035951108 hasPublicationYear "2020" @default.
• W3035951108 type Work @default.
• W3035951108 sameAs 3035951108 @default.
• W3035951108 citedByCount "19" @default.
• W3035951108 countsByYear W30359511082020 @default.
• W3035951108 countsByYear W30359511082021 @default.
• W3035951108 countsByYear W30359511082022 @default.
• W3035951108 countsByYear W30359511082023 @default.
• W3035951108 crossrefType "journal-article" @default.
• W3035951108 hasAuthorship W3035951108A5055733515 @default.
• W3035951108 hasAuthorship W3035951108A5056279223 @default.
• W3035951108 hasAuthorship W3035951108A5060211163 @default.
• W3035951108 hasConcept C103637391 @default.
• W3035951108 hasConcept C126322002 @default.
• W3035951108 hasConcept C138816342 @default.
• W3035951108 hasConcept C142724271 @default.
• W3035951108 hasConcept C159110408 @default.
• W3035951108 hasConcept C177713679 @default.
• W3035951108 hasConcept C18903297 @default.
• W3035951108 hasConcept C2776348555 @default.
• W3035951108 hasConcept C2777648638 @default.
• W3035951108 hasConcept C2777714996 @default.
• W3035951108 hasConcept C2778275353 @default.
• W3035951108 hasConcept C2779134260 @default.
• W3035951108 hasConcept C2780035454 @default.
• W3035951108 hasConcept C3008058167 @default.
• W3035951108 hasConcept C501593827 @default.
• W3035951108 hasConcept C519536355 @default.
• W3035951108 hasConcept C524204448 @default.
• W3035951108 hasConcept C71924100 @default.
• W3035951108 hasConcept C86803240 @default.
• W3035951108 hasConcept C89423630 @default.
• W3035951108 hasConcept C89623803 @default.

• next